Kang, Ju-HeeKorecka, MagdalenaFigurski, Michal J.Toledo, Jon B.Blennow, KajZetterberg, HenrikWaligorska, TeresaBrylska, MagdalenaFields, LeonaShah, NiraliSoares, HollyDean, Robert A.Vanderstichele, HugoPetersen, Ronald C.Aisen, Paul S.Saykin, Andrew J.Weiner, Michael W.Trojanowski, John Q.Shaw, Leslie M.Alzheimer's Disease Neuroimaging Initiative2017-09-222017-09-222015-07Kang, J.-H., Korecka, M., Figurski, M. J., Toledo, J. B., Blennow, K., Zetterberg, H., … for the Alzheimer’s Disease Neuroimaging Initiative. (2015). The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association, 11(7), 772–791. http://doi.org/10.1016/j.jalz.2015.05.0031552-5279https://hdl.handle.net/1805/14170INTRODUCTION: We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1-42), t-tau, and p-tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids. METHODS: Review publications authored or coauthored by ADNI Biomarker core faculty and selected non-ADNI studies to deepen the understanding and interpretation of CSF Aβ1-42, t-tau, and p-tau181 data. RESULTS: CSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non-ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies. DISCUSSION: Further studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease-modifying therapeutic trials.en-USPublisher PolicyAlzheimer Diseasecerebrospinal fluiddiagnosisAmyloid beta-PeptidesPeptide Fragmentstau ProteinsArticle